Upgrade to SI Premium - Free Trial

MiNK Therapeutics (INKT)

11.87 -0.88 (6.90%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (8/12/26)

Latest Headlines

Form 4 MiNK Therapeutics, Inc. For: Jun 04 Filed by: Ryan Barbara June 5, 2026 6:04 PM - SEC Filing MiNK Therapeutics Announces its Virtual 2026 Annual Shareholders Meeting June 3, 2026 4:30 PM - StreetInsider Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Holcomb John Bradley June 2, 2026 4:06 PM - SEC Filing Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Ryan Barbara June 2, 2026 4:06 PM - SEC Filing Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Corvese Brian June 2, 2026 4:06 PM - SEC Filing Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: Behner Peter June 2, 2026 4:05 PM - SEC Filing Form 4 MiNK Therapeutics, Inc. For: Mar 02 Filed by: WIINBERG ULF June 2, 2026 4:05 PM - SEC Filing MiNK Therapeutics doses first patient in phase 2 lung injury trial May 28, 2026 9:05 AM - StreetInsider MiNK Therapeutics Announces First Patient Dosed in Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury and Critical Illness May 28, 2026 9:04 AM - Globe NewsWire Agenus reports AI analysis shows improved response rates for cancer treatment May 21, 2026 5:00 PM - StreetInsider Agenus reports melanoma trial data for drug combination BOT+BAL May 21, 2026 5:00 PM - StreetInsider Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026 May 21, 2026 5:00 PM - BizWire Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC May 21, 2026 5:00 PM - BizWire MiNK shares new data on agenT-797 cell therapy at ATS conference May 20, 2026 11:07 AM - StreetInsider MiNK Therapeutics Reports New Data on agenT-797, an allo-iNKT Cell Therapy at ATS 2026; Simultaneously Published in Clinical Immunology Communications May 20, 2026 11:07 AM - Globe NewsWire Form 10-Q MiNK Therapeutics, Inc. For: Mar 31 May 15, 2026 4:24 PM - SEC Filing Agenus publishes phase 1b data for liver cancer drug combination May 15, 2026 4:11 PM - StreetInsider Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer May 15, 2026 4:11 PM - BizWire Form 8-K MiNK Therapeutics, Inc. For: May 15 May 15, 2026 8:03 AM - SEC Filing MiNK therapeutics starts randomized phase 2 trial for lung injury therapy May 15, 2026 7:31 AM - StreetInsider MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation May 15, 2026 7:30 AM - Globe NewsWire MiNK Therapeutics shows dual immune responses from single cell therapy May 12, 2026 7:37 AM - StreetInsider MiNK Therapeutics Presents Clinical Evidence That a Single, Off-the-Shelf, iNKT Cell Product Drives Context-Dependent Immune Responses at ASGCT 2026 May 12, 2026 7:35 AM - Globe NewsWire Agenus reports $4.6 million in pre-commercial revenue for Q1 2026 May 11, 2026 8:45 AM - StreetInsider Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development May 11, 2026 8:45 AM - BizWire MiNK Therapeutics to Report First Quarter 2026 Financial Results and Highlight Platform Progress Across iNKT Cell Therapy Programs May 8, 2026 4:30 PM - StreetInsider Form ARS MiNK Therapeutics, Inc. For: Dec 31 April 30, 2026 4:41 PM - SEC Filing Form DEF 14A MiNK Therapeutics, Inc. For: Jun 17 April 30, 2026 4:38 PM - SEC Filing Form 4 MiNK Therapeutics, Inc. For: Sep 23 Filed by: Holcomb John Bradley April 30, 2026 4:31 PM - SEC Filing H.C. Wainwright Reiterates Buy Rating on MiNK Therapeutics (INKT) April 23, 2026 7:12 AM - StreetInsider Form 3 MiNK Therapeutics, Inc. For: Mar 13 Filed by: Orilall Melissa April 9, 2026 4:16 PM - SEC Filing MiNK Therapeutics and Memorial Sloan Kettering to Present Phase II Study of agenT-797 Combination in PD-1 Refractory Gastroesophageal Cancer at AACR 2026 April 3, 2026 7:30 AM - Globe NewsWire Form 10-K MiNK Therapeutics, Inc. For: Dec 31 March 31, 2026 4:49 PM - SEC Filing MiNK Therapeutics (INKT) Misses Q4 EPS by 56c March 31, 2026 8:13 AM - StreetInsider Form 8-K MiNK Therapeutics, Inc. For: Mar 31 March 31, 2026 8:07 AM - SEC Filing Form 8-K MiNK Therapeutics, Inc. For: Mar 27 March 27, 2026 10:40 AM - SEC Filing Form 3 MiNK Therapeutics, Inc. For: Mar 13 Filed by: Charette Austin March 23, 2026 4:30 PM - SEC Filing Form 8-K MiNK Therapeutics, Inc. For: Mar 13 March 19, 2026 5:21 PM - SEC Filing MiNK Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Highlight Platform Expansion Across iNKT Cell Therapy Programs March 17, 2026 7:30 AM - StreetInsider Form 4 MiNK Therapeutics, Inc. For: Mar 09 Filed by: Ryan Barbara March 11, 2026 6:22 PM - SEC Filing MiNK Therapeutics partners with C-Further for pediatric cancer therapy March 10, 2026 5:59 AM - StreetInsider MiNK Therapeutics Announces Collaboration with C-Further to Advance PRAME-Targeted iNKT Cell Therapy for Pediatric Cancers March 10, 2026 5:30 AM - StreetInsider C-Further Unveils First Therapeutic Programmes Dedicated to Paediatric Oncology March 10, 2026 5:00 AM - BizWire Full Article List